In This Article:
GAITHERSBURG, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its participation in the TechBio track at Biotech Showcase and RESI JPM, both taking place during the annual JP Morgan Healthcare Conference in San Francisco, January 13–16, 2025.
At both Biotech Showcase and RESI JPM, BullFrog AI will highlight its proprietary BullFrog Data Networks®, a data insights tool powered by the bfLEAP™ platform. BullFrog Data Networks® evaluate high-dimension, multi-modal data in specific disease indications, providing a customized, visual representation of previously unknown relationships and pathways. The networks leverage a wide range of data inputs, including publicly available datasets such as the Human Cell Atlas (HCA), The Cancer Genome Atlas (TCGA), and Gene Expression Omnibus (GEO), as well as proprietary or custom data sources.
BullFrog Data Networks® address a key challenge faced by pharmaceutical and biotechnology companies: turning vast and complex datasets into actionable insights. The platform uses machine learning to holistically analyze data, revealing hidden insights that manual methods cannot uncover. These insights are presented in an intuitive visual format that enables users to explore individual nodes or clusters, examine relationships, and derive actionable conclusions.
BullFrog AI has demonstrated proof of concept for BullFrog Data Networks® in its own research and development pipeline, focusing on colorectal cancer and multiple neuropsychiatric indications. These networks have a wide range of applications, including target identification and validation, understanding mechanisms of action, optimizing clinical trials, and drug repurposing. By accelerating the generation of novel insights, BullFrog Data Networks® aim to transform approaches to drug development by reducing timelines and improving outcomes.
Powered by the bfLEAP™ platform, BullFrog Data Networks® are purpose-built to deliver answers to critical questions throughout the drug development lifecycle. From early target discovery to understanding drug safety and tolerability, the networks can help streamline development processes and optimize clinical trial design by identifying suitable patient populations for the appropriate trials. BullFrog Data Networks® represent an advancement in the Company's mission to revolutionize drug discovery and development.